| Filed On | Filing |
|---|---|
| 06 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027 |
| 29 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis |
| 13 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 |
| 22 Jul 2026 | SCHEDULE 13G/A |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 12, 2026, Cartesian Therapeutics, Inc. (the “Company”) held the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 24,151,536 shares of the Company’s common stock, par value $0.0001 per share (the “common stoc... |
| 09 Jun 2026 | 144 |
| 09 Jun 2026 |
8-K: Regulation FD Disclosure
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases |
| 02 Jun 2026 | 144 |
| 26 May 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +3 more
This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of May 22, 2026 (the “Closing Date”) is entered into among CARTESIAN THERAPEUTICS, INC., a Delaware ... |
| 06 May 2026 | SCHEDULE 13G/A |
| 30 Apr 2026 | S-8 |
| 30 Apr 2026 | 10-Q |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis |
| 28 Apr 2026 |
Proxy statement: annual meeting on June 12, 2026
CEO pay $4.3M, down 41% · say-on-pay vote |
| 28 Apr 2026 | DEFA14A |
| 06 Apr 2026 |
Form 4: Hoge Elizabeth, 10% owner and 1 other
Received 758,001 shares by exercise or conversion |
Loading...